<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305548</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-MCS</org_study_id>
    <nct_id>NCT04305548</nct_id>
  </id_info>
  <brief_title>Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma</brief_title>
  <acronym>ISG-MCS</acronym>
  <official_title>Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the
      activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced
      (locally advanced or metastatic)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, uncontrolled, multicenter, Italian, investigator-initiated, phase II clinical
      study to explore the activity of trabectedin in a population of patients aged ≥16 years with
      progressive, advanced (locally advanced or metastatic), HEY1-NCOA2 positive MCS) ,
      pre-treated with anthracycline-based chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall tumour Response Rate, according to RECIST v 1.</measure>
    <time_frame>At weeks 6</time_frame>
    <description>Response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choi criteria response rate</measure>
    <time_frame>At weeks 6, 12,18, 30, 42</time_frame>
    <description>Response rate according Choi criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 3 and 5 years</time_frame>
    <description>Proportion of patients who are still alive at 36 and 60 months after have started the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At 3 and 5 years</time_frame>
    <description>Survival without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>Month 6</time_frame>
    <description>Proportion of patient alive, without disease progression, after 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>At weeks 6, 12,18, 30, 42</time_frame>
    <description>Duration of time between the date of first documented response and the date of first documented progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to the treatment</measure>
    <time_frame>Week 3, week 6, week 9, week 12, week 18, week 24, week 36, week 48, week 60, week 72</time_frame>
    <description>Safety in term of grading of adverse event is evaluate from the firs treatment dose throughout the study according to CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Mesenchymal Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion</description>
    <arm_group_label>Trabectedin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 16 years old

          2. Histological centrally confirmed diagnosis of skeletal or extra-skeletal MCS with the
             documented presence of HEY1-NCOA2 fusion

          3. Locally advanced disease and/or metastatic disease

          4. Measurable or evaluable disease with RECIST v1.1

          5. Evidence of progression by RECIST v1.1 during the 6 months before study entry

          6. Patients must be pre-treated with at least one prior chemotherapy treatment containing
             anthracyclines for the advanced phase of disease and with a maximum of 3 lines

          7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          8. Adequate bone marrow function

          9. Adequate organ function

         10. Female patients of childbearing potential must have negative pregnancy test within 7
             days before initiation each cycle of chemotherapy.

         11. Cardiac ejection fraction ≥50% as measured by echocardiogram

         12. No history of arterial and/or venous thromboembolic event within the previous 12
             months

         13. The patient or legal representative must be able to read and understand the informed
             consent form and must have been willing to give written informed consent and any
             locally required authorisation before any study-specific procedures, including
             screening evaluations, sampling, and analyses.

         14. Any other factors, that, at judgment of investigator, could affect the safety of the
             patients according to the available trabectedin safety data

        Exclusion Criteria:

          1. Other primary malignancy with &lt;5 years clinically assessed disease free interval,
             except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to
             entail a low risk of relapse

          2. Previous treatment with radiation therapy within 14 days of first day of study drug
             dosing, or patients who have not recovered from adverse events due to agents
             previously administered

          3. Previous radiotherapy to 25% of the bone marrow

          4. Major surgery within 2 weeks prior to study entry

          5. Participation in another clinical study with an investigational product, which last
             dose was taken less than 4 weeks prior to the start of the treatment.

          6. Persistent toxicities (≥ grade 2) with the exception of alopecia, caused by previous
             anticancer therapies.

          7. Pregnancy or breast feeding

          8. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria

          9. Medical history of arterial thrombotic or embolic events such as cerebrovascular
             accident (including transient ischemic attacks), or pulmonary embolism within 6 months
             prior to the initiation of study treatment

         10. Known brain metastasis

         11. Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis)

         12. Known diagnosis oh human deficiency virus (HIV) infection

         13. Active or chronic hepatitis B or C requiring treatment with antiviral therapy

         14. Medical history of hemorrhage or a bleeding event ≥ Grade 3 within 4 weeks prior to
             the initiation of study treatment

         15. Evidence of any other serious or unstable illness, or medical, psychological, or
             social condition, that could jeopardize the safety of the subject and/or his/her
             compliance with study procedures, or may interfere with the subject's participation in
             the study or evaluation of the study results

         16. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation of the study drugs

         17. Expected non-compliance to medical regimens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <phone>39022390</phone>
    <phone_ext>2804</phone_ext>
    <email>silvia.stacchiotti@istitutotumori.mi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nuovo Ospedale di Prato</name>
      <address>
        <city>Prato</city>
        <state>Firenze</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <phone>0039057443</phone>
      <phone_ext>4766</phone_ext>
      <email>giacomogiulio.baldi@uslcentro.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>003906-22541</phone>
      <phone_ext>1123</phone_ext>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>0039-011-993</phone>
      <phone_ext>3623</phone_ext>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandra Longhi, MD</last_name>
      <phone>+390516366</phone>
      <phone_ext>199</phone_ext>
      <email>alessandra.longhi@ior.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Longhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCSS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <phone>+39022390</phone>
      <email>silvia.stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <email>giuseppe.badalamenti@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lee AF, Hayes MM, Lebrun D, Espinosa I, Nielsen GP, Rosenberg AE, Lee CH. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma. Appl Immunohistochem Mol Morphol. 2011 May;19(3):233-8. doi: 10.1097/PAI.0b013e3181fd6697.</citation>
    <PMID>21084965</PMID>
  </reference>
  <reference>
    <citation>Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, Dal Cin P, Antonescu CR, Singer S, Hameed M, Bovee JV, Hogendoorn PC, Socci N, Ladanyi M. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012 Feb;51(2):127-39. doi: 10.1002/gcc.20937. Epub 2011 Oct 27.</citation>
    <PMID>22034177</PMID>
  </reference>
  <reference>
    <citation>Morioka H, Takahashi S, Araki N, Sugiura H, Ueda T, Takahashi M, Yonemoto T, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Susa M, Nakayama R, Nishimoto K, Kikuta K, Horiuchi K, Kawai A. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer. 2016 Jul 14;16:479. doi: 10.1186/s12885-016-2511-y.</citation>
    <PMID>27418251</PMID>
  </reference>
  <reference>
    <citation>Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3.</citation>
    <PMID>19190116</PMID>
  </reference>
  <reference>
    <citation>Huvos AG, Rosen G, Dabska M, Marcove RC. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer. 1983 Apr 1;51(7):1230-7.</citation>
    <PMID>6825046</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chondrosarcoma, Mesenchymal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

